# Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

> **NCT07010835** · PHASE1,PHASE2 · RECRUITING · sponsor: **Excyte Biopharma Ltd** · enrollment: 189 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** YK012

## Key facts

- **NCT ID:** NCT07010835
- **Lead sponsor:** Excyte Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010835, "Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07010835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*